| AN ARTICLE A DAY, PICKED BY OUR EDITORS | | | Dread, fatigue, dรฉjร vu: the recently identified variant of concern, Omicron, certainly elicited some unpleasant feelings nearly two years into the COVID-19 crisis. While its emergence is rewriting the timetable for stamping out the pandemic, the endpoint remains the same: the world needs to adjust to managing COVID-19 as an endemic disease. Get up to speed on what could lie ahead with an in-depth look at how Omicron affects a range of scenarios based on infectiousness, immune evasion, and disease severity. New therapeutics, booster doses of vaccines, and public-health measures are also covered. You don’t want to miss the latest update to “When will the COVID-19 pandemic end.” | | — Torea Frey, managing editor, Seattle | | | The Omicron variant is spreading rapidly. What does it hold in store? Our analysis offers some scenarios to understand potential outcomes. We also look at the effects of boosters, the potential waning of vaccine efficacy, and new oral therapeutics. | | | Subscribe to McKinsey’s new Daily Read newsletter to get our editors’ pick of one must-read article each weekday—and why it shouldn’t be missed. | | | Did you enjoy this newsletter? Forward it to colleagues and friends so they can subscribe too.
Was this issue forwarded to you? Sign up for it and sample our 40+ other free email subscriptions here. | | | This email contains information about McKinsey’s research, insights, services, or events. By opening our emails or clicking on links, you agree to our use of cookies and web tracking technology. For more information on how we use and protect your information, please review our privacy policy. | | You received this email because you subscribed to our Healthcare Systems & Services alert list. | | | | Copyright © 2021 | McKinsey & Company, 3 World Trade Center, 175 Greenwich Street, New York, NY 10007 | | |
